<DOC>
	<DOCNO>NCT00213278</DOCNO>
	<brief_summary>This study examine whether Vinblastine effective drug shrink low grade glioma brain tumor child , side effect .</brief_summary>
	<brief_title>Phase 2 Study Vinblastine Children With Recurrent Refractory Low Grade Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>&lt; 21 year age original diagnosis histological verification low grade glioma ( glial tumor , neuronal tumor chiasmatichypothalamic tumor ) original diagnosis evidence tumor recurrence progression MRI contrast CT Karnofsky Lansky performance status 0,1 2 life expectancy great equal 2 month adequate organ bone marrow function within 7 day start treatment Vinblastine absolute neutrophil count ( ANC ) &gt; 1000/uL platelet count &gt; 100,000/uL ( transfusion independent ) serum creatinine &lt; 1.5 x normal age write informed consent sign subject and/or subject 's parent/legal guardian recover acute toxic effect prior chemotherapy , immunotherapy radiotherapy chemotherapy within 2 week entry study ( 4 week prior nitrosourea use ) less 7 day since completion therapy biologic agent le 2 month since cranial/spinal radiation receive stable dose dexamethasone le one week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>glioma</keyword>
	<keyword>brain tumour</keyword>
	<keyword>cancer</keyword>
	<keyword>pediatrics</keyword>
	<keyword>vinblastine sulfate</keyword>
</DOC>